BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference

NESS ZIONA, Israel, September 8, 2015 /PRNewswire/ --

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Company's CEO, Dr. Ron Babecoff, will participate in the Rodman & Renshaw 17th Annual Global Investment Conference, taking place at the St. Regis hotel in New York from September 8-10, 2015.

BiondVax CEO, Dr. Ron Babecoff, is scheduled to present on Thursday, September 10, 2015 at 10:25am Eastern Time.  The corporate presentation which Dr. Babecoff will present at the conference is available for download from the investor relations section of BiondVax's website.

At the conference there will be an opportunity for investors to meet one-on-one with Dr. Ron Babecoff. In addition, Dr. Babecoff will be meeting investors and analysts throughout the week on a non-deal roadshow in both Boston and New York. Investors interested in meeting with management should contact the Investor Relations team at BiondVax at [email protected].

About BiondVax Pharmaceuticals Ltd 

BiondVax is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.

BiondVax's technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

For further information, please contact:

Company Contact
Limor Chen, Director of  BD
[email protected]

Investor Relations Contact
GK Investor Relations
Kenny Green, Partner
+1-646-201-9246
[email protected]

SOURCE Biondvax Pharmaceuticals Ltd

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED